**Supplemental Table 1.** Number of chronic fatigue symptoms (first and fourth quartile Q1, Q4) according to the characteristics of the patients upon hospital admission.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | 0-4 weeks | | | 4-12 weeks | | | >12 weeks | | |
| Q1 (n; %)  n=47 | Q4 (n; %)  n=59 | p-value | Q1 (n; %)  n=50 | Q4 (n; %)  n=42 | p-value | Q1 (n; %)  n=69 | Q4 (n; %)  n=59 | p-value |
| Demographics | | | | | | | | | |
| Age (years) | 60 (46-67) | 64 (43-63) | 0.057 | 59 (46-69) | 57 (48-63) | 0.268 | 57 (44-67) | 59 (49-65) | 0.513 |
| Female sex, n (%) | 13 (27.66) | 32 (54.24) | 0.006 | 15 (30.00) | 26 (61.90) | 0.002 | 20 (28.99) | 38 (64.41) | <0.001 |
| Comorbidities | | | | | | | | | |
| Hypertension, n (%) | 21 (44.68) | 26 (44.07) | 0.949 | 25 (50.00) | 17 (40.48) | 0.369 | 28 (40.58) | 26 (44.07) | 0.690 |
| Hypercholesterolemia, n (%) | 11 (23.40) | 11 (18.64) | 0.548 | 13 (26.00) | 9 (21.43) | 0.608 | 17 (24.64) | 11 (18.64) | 0.411 |
| Obesity, n (%) | 18 (38.30) | 23 (38.98) | 0.942 | 19 (38.00) | 18 (42.86) | 0.636 | 25 (36.23) | 22 (37.29) | 0.901 |
| Smoking, n (%) | 12 (25.53) | 21 (35.59) | 0.266 | 18 (36.00) | 15 (35.71) | 0.978 | 22 (31.83) | 18 (30.51) | 0.867 |
| Diabetes mellitus, n (%) | 8 (17.02) | 9 (15.25) | 0.806 | 8 (16.00) | 9 (21.43) | 0.504 | 10 (14.49) | 10 (16.95) | 0.703 |
| Ischemic heart disease, n (%) | 2 (4.26) | 6 (10.17) | 0.296 | 3 (6.00) | 5 (11.90) | 0.461 | 4 (5.80) | 8 (13.56) | 0.223 |
| Atrial fibrillation, n (%) | 2 (4.26) | 5 (8.47) | 0.459 | 3 (6.00) | 3 (7.14) | 1.000 | 4 (5.80) | 5 (8.47) | 0.732 |
| Chronic heart failure | 2 (4.650 | 2 (3.45) | 1.000 | 2 (4.44) | 1 (2.44) | 1.000 | 3 (4.69) | 2 (3.64) | 1.000 |
| Prior CNS disease, n (%)  Stroke in the past  Dementia  Depression  Anxiety disorders | 8 (17.02)  0 (0.00)  2 (4.26)  5 (10.64)  1 (2.13) | 17 (28.81)  6 (10.17)  1 (1.69)  11 (18.64)  4 (6.78) | 0.155  0.033  0.584  0.252  0.479 | 9 (18.00)  1 (2.00)  3 (6.00)  6 (12.00)  2 (4.00) | 13 (30.95)  4 (9.52)  2 (4.76)  8 (19.05)  3 (7.14) | 0.147  0.174  1.000  0.348  0.657 | 13 (18.84)  1 (1.45)  2 (2.90)  9 (13.04)  3 (4.35) | 17 (28.81)  5 (8.47)  6 (10.17)  8 (13.56)  4 (6.78) | 0.184  0.094  0.142  1.000  0.703 |
| Asthma / COPD, n (%) | 2 (4.26) | 6 (10.17) | 0.296 | 3 (6.00) | 7 (16.67) | 0.096 | 4 (5.80) | 9 (15.25) | 0.087 |
| Neoplasm, n (%)  -active  - in the past | 1 (2.33)  6 (12.77) | 2 (3.45)  2 (3.39) | 1.000  0.135 | 1 (2.22)  5 (10.00) | 2 (4.88)  2 (4.76) | 0.603  0.448 | 2 (3.13)  6 (8.70) | 1 (1.82)  3 (5.08) | 1.000  0.504 |
| Chronic kidney disease stage 3, n (%) | 3 (6.38) | 3 (5.08) | 1.000 | 3 (6.00) | 2 (4.76)\_ | 1.000 | 4 (5.80) | 2 (3.39) | 0.686 |
| Alkohol abuse, n (%) | 1 (2.13) | 2 (3.39) | 1.000 | 1 (2.00) | 2 (4.76) | 0/590 | 2 (2.90) | 2 (3.39) | 1.000 |
| Treatment | | | | | | | | | |
| Anticoagulant, n (%) | 3 (6.38) | 4 (6.78) | 1.000 | 5 (10.00) | 2 (4.76) | 0.448 | 5 (7.25) | 5 (8.47) | 1.000 |
| Beta-adrenolytic, n (%) | 8 (17.02) | 12 (20.34) | 0.665 | 11 (22.00) | 8 (19.05) | 0.727 | 13 (18.84) | 10 (16.95) | 0.781 |
| Antidepressant, n (%) | 5 (10.64) | 13 (22.03) | 0.121 | 6 (12.00) | 9 (21.43) | 0.222 | 9 (13.04) | 10 (16.95) | 0.536 |
| Neuroleptic, n (%) | 1 (2.13) | 2 (3.39) | 1.000 | 2 (4.0) | 1 (2.38) | 1.000 | 3 (4.350 | 1 (1.69) | 0.623 |
| First COVID-19 symptoms | | | | | | | | | |
| Anosmia n (%) | 7 (14.89) | 11 (18.64) | 0.605 | 7 (14.00) | 6 (14.29) | 0.968 | 11 (15.94) | 10 (16.95) | 0.878 |
| Cough, n (%) | 40 (85.11) | 48 (81.36) | 0.609 | 41 (82.00) | 35 (83.33) | 0.866 | 56 (81.16) | 52 (88.14) | 0.279 |
| Dyspnea, n (%) | 31 (65.96) | 40 (67.80) | 0.841 | 35 (70.00) | 30 (71.43) | 0.881 | 47 (68.12) | 42 (71.19) | 0.707 |
| Fever, n (%) | 40 (85.11) | 53 (89.93) | 0.461 | 42 (84.00) | 38 (90.48) | 0.358 | 56 (81.16) | 51 (86.44) | 0.421 |
| Gastrointestinal, n (%) | 15 (31.91) | 19 (32.20) | 0.974 | 16 (32.00) | 12 (28.57) | 0.721 | 26 (37.68) | 18 (30.51) | 0.394 |
| Hospital admission | | | | | | | | | |
| Oxygen therapy, n (%)  Not required  Nasal cannula  Simple face mask  Non-invasive ventilation | 7 (14.89)  33 (70.21)  7 (14.80)  0 (0.00) | 7 (11.86)  38 (64.41)  14 (23.72)  0 (0.00) | 0.214 | 8 (16.00)  33 (66.00)  9 (18.00)  0 (0.00) | 4 (9.52)  26 (61.90)  12 (28.57)  3 (7.14) | 0.416 | 9 (13.04)  46 (66.67)  14 (20.29)  0 (0.00) | 6 (10.127)  36 (61.02)  17 (28.81)  0 (0.00) | 0.746 |
| MEWS score, n (%)  1  >1 | 39 (82.98)  8 (17.02) | 43 (72.88)  9 (21.43) | 0.217 | 40 (80.00)  10 (20.00) | 28 (66.67)  14 (33.33) | 0.147 | 54 (78.26)  15 (21.74) | 41 (69.49)  18 (30.51) | 0.258 |
| CRP (mg/dL) (first 24 hours) | 64.2 (36.9-119) | 78.4 (33.9-110) | 0.913 | 67.2 (36.9-115) | 78. (23-122) | 0.931 | 64 (37-110) | 76.9 (30.8-123) | 0.517 |
| IL-6 (pg/ml) (first 48 hours) | 36.4 (16.7-55.2) | 27 (8.9-53.9) | 0.259 | 38.6 (12.2-55.2) | 28.2 (11.2-59.2) | 0.563 | 32.5 (14.6-49.9) | 28.5 (10.1-62.1) | 0.549 |
| Procalcitonin (ng/ml) (first 24 hours) | 0.08 (0.04-0.17) | 0.09 (0.05-0.18) | 0.498 | 0.09 (0.05-0.17) | 0.08 (0.04-0.17) | 0.996 | 0.09 (0.05-0.17) | 0.09 (0.04-0.19) | 0.867 |
| WBC (x103) (first 24 hours) | 5.68 (4.33-8.62) | 5.17 (3.88-7.34) | 0.361 | 5.52 (4.33-8.05) | 5.56 (4.01-7.39) | 0.820 | 5.2 (4.0-7.0) | 6.3 (4.8-7.4) | 0.113 |